Cardiac Troponins: Current Approach From Laboratory to Clinic

Özet

Cardiac biomarkers should be capable of objectively evaluating the physiological status of the cardiomyocytes, the pathological process and the pharmacological response to a therapeutic agent. A good cardiac biomarker should have high specificity and sensitivity, early diagnosis, reflecting the area of myocardial infarction, reperfusion, and showing reinfarction. Cardiac troponins are now accepted as the gold standard due to their high sensitivity and specificity. Studies have shown that high-sensitivity cardiac troponin (hs-cTn) produced by improving the analytical performance of conventional cTns can also be detected in the circulation up to the first two hours following the AMI. Conventional cTn measurements can measure the upper limit value (URL) of 99% only with sensitivity (CV) above 20%, whereas with hs-cTn, these values can measure with CVs of 10% or less. The use of ng/L (or pg/mL) is recommended for cardiac troponins. Serial cardiac troponin measurements are important in distinguishing acute cardiac events from chronic and inflammatory events. Significant changes in ACS are observed, while changes in other events remain absent or limited. There are many studies showing that Hs-cTn contributes positively to the risk assessment of patients. High cTn levels are associated with poor prognosis and risk of death.